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Abst rac t
Introduction: Venom immunotherapy treatment (VIT) is the only causal treatment of hymenoptera venom anaphy-
laxis, which aims to provide long-lasting immunoprotection against severe reactions to subsequent stings.
Aim: To reassess the compliance of VIT procedures in the Polish allergy centres with the European guidelines. 
Material and methods: A structured questionnaire survey conducted in all 33 VIT-centres. The response rate was 94%.
Results: The ultrarush initial protocol was the most common protocol (71%, n = 22), usually lasting for 3.5 h (50%,  
n = 7). The most frequent (36%, n = 11) time interval from the initial to the first maintenance dose (MD) was 14 days, 
ranging from 7 to 35 days. All centres used an MD of 100 µg. The most frequent time interval between subsequent 
MDs was 4 weeks (58%, n = 18). Five years’ of VIT was declared by 71% (n = 22). Before the termination of treat-
ment, more than half of the centres (58%, n = 18) performed sIgE and almost half (42%, n = 13) performed skin tests. 
To confirm VIT efficacy, few centres (26%, n = 8) conducted the sting challenge. About half of centres provided the 
patients with an adrenalin auto-injector both at the time of initial diagnostics and at the end of treatment. More 
than half (55%, n = 17) used antihistamines in all patients. Almost half (45%, n = 14) declared to stop treatment with 
β-blockers and almost one fourth (23%, n = 7) discontinued angiotensin-converting-enzyme inhibitors. 
Conclusions: In the most important procedures, there is a very high compliance with the guidelines. In the areas 
where the guidelines are not precise, we observed a large spread of results.
Key words: venom allergy, immunotherapy, national survey.
Introduction
Venom immunotherapy treatment (VIT) is the only 
causal treatment of hymenoptera venom anaphylaxis 
(HVA), which aims to provide long-lasting immunopro-
tection against severe reactions to subsequent stings. 
The rules of treatment to be the most safe and effective, 
are indicated by the up-dated evidence-based guidelines 
worldwide [1–4]. The first European guidelines on VIT were 
published by the European Academy of Allergy and Clinical 
Immunology (EAACI) in 1987, and updated in 2005 [5, 6], 
which initiated the development of national guidelines, in-
cluding Polish [7], British [8] and others [9, 10]. An up-date 
of the EAACI VIT recommendations has been published in 
2018 year [11, 12]. Even though the present-day recommen-
dations should guarantee the optimal procedures in the 
treatment of HVA, current analysis shows that the actual 
practices differ in some aspects [13–16].
Aim
The aim of the study was to reassess the treatment 
procedures concerning HVA in Polish specialist centres and 
to evaluate their compliance with the European guidelines. 
Material and methods
The study was conducted in 33 Polish allergy centres, 
which all specialize in the treatment of HVA patients. The 
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survey was carried out by means of a structured ques-
tionnaire, which was an extended version of a question-
naire used in the first such study conducted in the United 
Kingdom [13] and in the previous Polish study [14]. 
The survey employed the computer assisted web in-
terview (CAWI) method, using the LimeSurvey® software 
installed at the Jagiellonian University Medical College 
web server [17]. An email with an invitation to the study 
and a personalized link to the questionnaire, was sent to 
the head of each centre. In case of a lack of an answer, 
two email reminders were sent 1 week apart, followed up 
with a telephone reminder. The response rate was 94% 
(31 centres answered), two centres did not fill out the 
questionnaire, one of which only performs diagnostics 
of HVA. Results are not supported by statistical tests be-
cause the paper presents real data. 
Results
Forty two percent (n = 13) of Polish centres treated 
exclusively adults, 26% (n = 8) dealt only with children, 
while 32% (n = 10) of centres treated both age groups 
(Figure 1). The total number of VIT-treated patients in 
2015 was 3,090, with an adult to child ratio of 5 : 1. In 
94% (n = 29) of centres, treatment was performed as an 
inpatient procedure).
Venom preparation
Two types of venom extracts are available in Poland: 
unpurified aqueous and depot extracts. During the up-
dosing (UpD), most of the centres (87%, n = 27) used 
only aqueous extracts, 3% (n = 1) used only depot ones, 
while 10% (n = 3) of centres work on both formulations. 
During the maintenance dose (MD), exclusively the aque-
ous venom preparations were used in 45% (n = 14) of 
centres, followed by the depot extracts (29%, n = 9) and 
26% (n = 8) of centres used both types of extracts. The 
same extract, during both UpD and MD, was used in 
48% (n = 15) of the centres, while almost one sixth (16%, 
n = 5) switched from an aqueous extract to a depot one 
during the MD, one fourth (26%, n = 8) began with an 
unpurified aqueous extract and continued with the same, 
10% (n = 3) began with one of the two and continued 
only with the depot extract. Only 6% (n = 2) changed the 
aqueous extract to the other.
Figure 1. The location of the Hymenoptera venom allergy treatment centres, and number of patients diagnosed in par-
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Initial treatment (up-dosing – UpD)
The ultrarush (UR) protocol of one day was the most 
common treatment regimen used in 71% (n = 22) of the 
centres, followed by the  rush protocol of a few days 
(16%, n = 5) and the cluster protocol of a few weeks (13%, 
n = 4). None of the centres declared to use the conven-
tional protocol. The reasons for the common applica-
tion of the UR were: short duration of treatment (32%, 
n = 10), rapid immunoprotection (19%, n = 6) and the 
economic aspect (9%, n = 3), including distance from the 
patient’s place of living to the VIT centre. 
The UR mostly lasted 3.5 h (50%, n = 7) or 4 h (29%, 
n = 4). According to all answers (n = 14), the duration varied 
from 3 to 8 h. The cumulative dose of the venom extract 
in this protocol was 101.1 µg (36%, n = 6) or 111.0 µg (23%, 
n = 3), respectively; though 1/3 of centres did not respond to 
this question, including these administering protocols other 
than the UR protocols. 
If the patient during the UpD VIT, despite the premedi-
cation with antihistamines, revealed systemic reactions of 
grades 2 to 4 according to the Mueller’s classification, then 
most centres continued treatment by changing the protocol 
to another one (70%, n = 22), but few continued changing 
the protocol individually (15%, n = 5). Some discontinued 
immunotherapy providing the patient with an adrenalin 
auto-injector (AAI), or practiced other strategies (Table 1).
Maintenance treatment (maintenance dose – MD)
The most common time interval from UpD to the first 
MD was 14 days (36%, n = 11), in 68% (n = 21) of centres it 
was no longer than 15 days, while with respect to all an-
swers, this period ranged from 7 to 35 days. All centres used 
an MD of 100 µg. The first MD was usually divided into 50 + 
50 µg (74%, n = 23), less frequently was applied as a single 
dose of 100 µg (10%, n = 3). There were also few patterns 
used by individual centres: 20 + 30 + 50 µg (6%, n = 2), 
30 + 70 µg and 20 + 40 + 40 µg (3% each, n = 1) or other 
schemes “depending on previous UR tolerance” (3%, n = 1).
The most frequent time interval between subsequent 
MDs was 4 weeks (58%, n = 18) regardless of the kind of 
venom preparation, followed by 6 weeks (16%, n = 5), and 
up to 8 weeks reported also by 16% (n = 5). The 6-week 
MD intervals were over three times more frequently applied 
with the depot extract (24% of centres, n = 4) than with 
the aqueous ones (7%, n = 1). Eight weeks were regarded 
as a maximum acceptable MD interval by 48% of centres 
(n = 15), followed by 6 weeks (36%, n = 11). A very few (10%, 
n = 3) centres accepted a maximum interval of 12 weeks. 
Treatment duration
Over two thirds of centres (71%, n = 22) declared that 
they conduct VIT for exactly 5 years, followed by 29% (n = 9) 
applying it for 3 to 5 years. Different lengths of treatment 
were declared by 81% (n = 25) of the centres for patients 
with mastocytosis, and among them over half (63%, n = 
10) declared lifelong treatment of those patients. About one 
fourth of centres (26%, n = 8) used a different treatment 
duration in patients with an elevated baseline serum trypt-
ase (bsT), however, 9% (n = 3) of centres declared that they 
have not had any such patients. A different (no precised) 
treatment duration was mentioned by 3% (n = 1) of the 
centres for beekeepers’ families, and by 10% (n = 3) of the 
centres for patients with cardiovascular disease.
Assessmentoftreatmentefficacybeforeits
termination
Before the termination of treatment, more than half 
of the centres (58%, n = 18) performed venom specific 
IgE (sIgE) while almost half (42%, n = 13) performed skin 
tests. In presence of positive results (either blood or skin 
tests), two thirds of the centres (68%, n = 21) did not 
extend the treatment period, 13% (n = 4) of centres de-
clared that they usually extend the treatment exclusively 
in patients with pre-treatment severe anaphylaxis, 3% 
(n = 1) in all patients irrespective of Mueller’s grade, 
whereas 16% (n = 5) depending on the following sce-
narios during VIT: positive sting challenge (SC) response, 
Table 1. Management of patients with repeated systemic grade 2–4 reactions during the incremental dose of venom 
preparation, regardless of antihistamine treatment
Alternative interventions N Percent
Change of protocol to the cluster one 13 42
Change of protocol to the conventional one 5 15
Change of protocol to the rush one 2 6
Change of protocol to the ultrarush one 2 6
Start VIT from the beginning with an individually chosen protocol aiming to accede maintenance dose over 100 µg 3 9
Continue treatment by lowering to the last well-tolerated dose 2 6
Continue VIT combined with premedication with systemic corticosteroids 1 3
Discontinuation of immunotherapy with a recommendation for the patient to apply AAI 2 6
No answer 1 3
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Table 2. Adrenaline autoinjector (AAI) prescription approach to hymenoptera venom allergic patients, at different 
phases of the treatment






All patients 15 (47) 21 (68) 16 (53)
Only those with grade 2 to 4 anaphylactic reactions 13 (41) 3 (10) 3 (10)
Only those with grade 3 to 4 severe anaphylactic reactions 3 (9) 6 (19) 6 (19)
Frequently exposed to stinging and experiencing LLR 1 (3)
In grade 1 reaction and parents’ request 1 (3) 1 (3)
Only in individual cases; grade 4, never stung during the VIT 1 (3)
Sometimes yes (no explanations) 1 (3)
No 3 (10)
grade 2–4 reaction due to a field sting or severe reaction 
to treatment venom preparation. To confirm VIT efficacy 
some of the centres conducted the SC regardless of the 
kind of the culprit insect (10%, n = 3) or only in case of 
a bee venom allergy (13%, n = 4). One centre (3%, n = 1) 
did not specify its criterion. No centre performed a SC 
more than once per patient. The evaluation of IgG4 was 
performed by 13% (n = 4) of centres either during the 
treatment period or before its termination. 
Medication
Adrenaline auto-injector prescription
About half of centres provided AAI to all patients re-
ferred for diagnostics regardless of severity of systemic 
reactions and a slightly smaller portion of the centres 
only to those patients who had a history of a pre-diag-
nostic anaphylaxis from 2 to 4 of Mueller’s grades. In VIT-
treated patients, AAI was prescribed by most of centres 
regardless of the degree of an anaphylactic reaction. At 
the end of the VIT, half of the centres prescribed AAI to all 
their patients (Table 2). All centres provided AAI to every 
patient with mastocytosis, regardless of the effectiveness 
of the immunotherapy.
Pre-treatment with antihistamines
More than half of the centres used antihistamines in 
all patients during the initial protocol and almost half of 
the centres declared using them in all patients during the 
maintenance dose. A very few centres used those drugs 
in case of a systemic side reaction (SSR) (Table 3).
    
Cardiovascular treatment 
Almost half (45%, n = 14) of the centres declared that 
they had stopped treatment with β-blockers and almost 
one fourth (23%, n = 7) discontinued angiotensin-con-
verting-enzyme inhibitors (ACEI), while 3% (n = 1) only 
reduced the ACEI dose before VIT introduction. Mean-
while, one third of centres (29%, n = 9) did not change 
the cardiovascular treatment. 
Discussion
Presented data represent nearly the whole popula-
tion of specialists applying VIT in Poland. The data are 
discussed with reference to the previous and current 
EAACI guidelines (Table 4) as well as in comparison to 
the British, French and previous Polish studies [13–16]. 
The European guidelines are intended for all countries, 
which are members of the EAACI and thus it is a disap-
pointment that such a small number of national reports 
exist on the correspondence of real-life practice with 
the guidelines.
VIT treatment organization
In comparison to 2009, we observed both an increase 
in the number of specialist centres and in the number 
of centres treating both age groups [14]. Currently, about 
one third of Polish centres treat both children and adults, 
while in the UK only one fifth of the centres do [15]. Adult 
care centres dominate both in Poland and in the UK (42% 
vs. 58%), which corresponds with the higher prevalence 
of HVA in the older population [18]. The total number of 
patients treated with VIT in 2015 in Poland was just over 
3,000. Considering the average of systematic reactions to 
hymenoptera stings amongst the European adult popu-
lation (3% to 8.9%) [18], and the population of Poland 
(approximately 38 millions) we can hypothesise that this 
type of allergy goes undiagnosed.
Venompreparationandimmunotherapy
VIT is performed by the subcutaneous route and 
consists of an UpD phase when immunoprotection is 
achieved, and an MD phase, which is crucial for main-
taining the long follow-up efficacy. The current and pre-
vious EAACI guidelines present four protocols, but do 
not indicate a specific protocol for the initial dose [6, 
12]. Thus, Polish doctors often choose the initial protocol 
based on the bibliography data [19–22], their experience, 
opinion on safety and effectiveness of the protocol as 
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well as economic factors (i.e. costs of the protocol or re-
imbursement regulations) [23].
In Poland we observed a growing preference for UpD 
immunotherapy ultrarush protocols (cumulative dose of 
111.1 µg by Muller or of 101.1 µg by Birnbaum) [24, 25] (71% 
vs. 58% in 2009 [14]) as well as the lack in use of the con-
ventional protocol. The UR protocol is the most commonly 
(60%) reported by the French authors [16], while in the 
UK the most common protocol remains the conventional 
one (76% vs. 92% during the previous study) [13, 15]. This 
difference may arise from the fact that in Poland, VIT is 
performed as an in-hospital procedure, in the UK it is an 
outpatient one, whereas in France, UpD is given in inpa-
tient and continued in outpatient settings [15, 16]. 
The EAACI guidelines of 2005 and 2017 do not specify 
the time interval between UpD and MD [6, 12]. The only 
reference to the recommended time interval comes from 
the first EAACI guidelines on VIT [5] and from subcuta-
neous immunotherapy standards [26]. As a result of the 
audit, the areas in which the answers showed a large 
variance were identified (Table 4). They concern the du-
ration of the UR protocol (from 3 to 8 h) and the time 
interval between the completion of the UpD and the ad-
ministration of the first dose of MD (from 7 to 35 days). 
Table 3. Pre-treatment with antihistamines with respect 
to the treatment phase






To all patients during VIT 17 (55) 15 (48)
In cases of LLR after injection 12 (39) 16 (52)
In cases of SSR after injection 2 (7) 2 (7)
In all cases of atopy 1 (3) 1 (3)
Asthma, cardiovascular diseases – 3 (10)
In majority of patients – 1 (3)
Table 4. A comparison of Polish practices of VIT with respect to the 2005 and 2017 EAACI guidelines 
Point for discussion Polish VIT 2016 practices EAACI Guidelines 2005
Bonifazi et al.
EAACI Guidelines 2017 
Sturm et al.




Aqueous preparation for UpD with R/UR, depot for UpD with conventional 
protocol
UpD
Change of protocol when 
2–4 SR during UpD
3–8 h
6 cum. doses from 100 to 
111.1 µg
81%
Not precisely indicated by the guidelines
– Length of rapid (UR, R) protocols





7 to 35 days
6 schemes
–
Indicated by the guidelines:
– 100 µg
– Interval
– 3–5 years treatment
Not precisely indicated by the guidelines:
– Interval from UpD to MD 
– Fractioning of the first MD
–  Protocol of increasing to 200 µg, when react to field sting or venom 
extract on VIT
– Anti-IgE dosing for premedication 
Diagnostic tests before VIT 
termination
≈50% Limited predictive value with regard to long-term protection after VIT
Sting challenge ≈25% Before taking a decision on VIT 
termination
If available as early as possible 
Supply with AAI ≈50% before, during and 
after VIT.
100% in severe reactors 
and mastocytosis patients
Patients allergic to hymenoptera 
venoms should carry an emergency 
kit for self-administration, especially 
during the insect season
In all mastocytosis patients
In all moderate to severe reactors 
after terminating VIT if risk factors 
for treatment failure are present
Pre-treatment with H1 
antihistamines 
≈50% 1–2 days before VIT, to be continued 
until the MD has been well 
tolerated at least for 3 times
1–2 h before MD, sometimes b.i.d.
Approach to cardiovascular 





Substitution of β -blockers or ACEI 
should be discussed
No contraindications to continue 
β-blockers.
Negative influence of ACEI might 
be overestimated 
UpD – up-dosing protocol, UR – ultrarush, R – rush, SR – systemic reactions, MD – maintenance dose, AA – adrenaline autoinjector, b.i.d. – bis in die (twice 
a day), ACEI – angiotensine inhibitors.
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Differentiation is common, for example, French authors 
reported one month between UpD and the first MD [16].
In case of complications in the UpD VIT phase, ac-
cording to the recommendations, doctors should con-
tinue VIT by restarting with a slower protocol. Sixty one 
percent of Polish centres followed this recommendation 
in the current study vs. 31% in the 2009 study [14]. There 
is a wide variation in behaviour in European countries; 
Poland is like France, however, the UK is different, where 
VIT is interrupted in such circumstances [13, 15, 16]. There 
is no good explanation for a very rare practice to acceler-
ate the UpD protocol in case of complications. 
There is a high compliance in Poland and other coun-
tries with the EAACI guidelines in respect to the recom-
mended kind of the venom extract (aqueous, depot) vs. 
VIT protocol, the recommended time interval between 
subsequent MDs [13, 15, 16] and nominal value of MD. 
However, single centres in Poland used depot prepara-
tions for cluster or rush/ultra-rush UpD, probably for 
safety reasons [27]. Currently all centres in Poland (vs. 
92% in 2009) [14] use MD of 100 µg, similarly to practices 
in France (96% centres) and in the UK (89% vs. 98%) [13, 
15, 16]. The most frequent time interval between subse-
quent MDs is 4 weeks, what is partially compliant with 
the guidelines which suggest to progressively prolong the 
interval after the first year of treatment. Our question-
naire did not contain such answer option. 
Also a high congruence with the recommendations 
concerns the VIT treatment time of 3 to 5 years, with the 
preference for the upper limit [6, 12]. In Poland, 5 years 
of treatment predominates (now 68% vs. 73% in 2009, 
respectively). In France, half of practitioners treated pa-
tients for 5 years [16], while in the UK, probably for the 
economic reasons, currently 3 years’ treatment is mainly 
practiced (83% of all VIT practitioners vs. 55% previously) 
[13, 15]. In Poland, the longer VIT duration is usually ap-
plied in case of patients with mastocytosis, while only 
one fourth of Polish centres extend VIT duration in case 
of the elevated bsT in patients without mastocytosis. All 
recommendations propose that a longer period or life-
long treatment should be considered in patients with 
a high risk of relapses – severe initial sting reactions and 
systemic side-effects during VIT, both the most frequent 
in mastocytosis patients, as well as in the bee venom 
allergic ones [4, 6, 8, 12]. 
Assessmentoftreatmenteffectivenessbeforeits
termination
Both previous and current EAACI guidelines state that 
size of positive skin test reactions, as well as sIgE concen-
trations have a limited predictive value with regard to 
long-term protection after VIT. However, if both skin tests 
and sIgE become negative, VIT may be stopped after 
3 years [6]. Currently, at VIT termination about 40% of 
Polish centres perform skin tests and almost 60% per-
form sIgE (vs. 46% in previous study) [14], which is two 
times higher than in the UK (30% in 2014 vs. 50% in 
2008) [13, 15]. Our data are similar to French data where 
almost two thirds of practitioners check sIgE at the end 
of treatment [16]. Positive results influence decision-
making in all countries, meaning longer than standard 
treatment time in Poland (now about 30% vs. 20% pre-
viously), in the UK (now 5% vs. 22% in 2008), in France 
almost half [13–16]. Though with the respect to the last 
guidelines, combined with the economic reasons, neither 
skin testing results nor specific IgE are recommended at 
the termination of treatment. Evaluation of IgG4 level 
during VIT or before its termination, is not recommended 
by the guidelines [6, 12], but it is still practiced in Poland 
by about 10% of centres; this value has increased from 
8% to 13% [14]. The reason may be the belief of some 
authors that IgG4 can serve as a marker of successful VIT, 
while it seems rather to be a marker of exposure [28, 29]. 
In the UK, monitoring VIT by means of IgG
4
 antibodies 
was never applied [13, 15], while in France it was done by 
5% of practitioners [16]. 
Sting challenge (SC) is regarded as the most relevant 
marker of successful VIT treatment, followed by a reac-
tion to a natural field sting as both indicate the tolerance 
and immunoprotection [30, 31]. In Poland, SC remains still 
rarely available in practice as about 75% of centres (vs. 
50% out of 26 centres in 2009) did not perform it at all. 
Its rare application is mainly due to practical aspects and 
experience limitations [14]. In the UK, according to the 
previous audit, almost all centres did not practice the SC, 
whereas currently such data are unavailable, similarly for 
France [13, 15, 16].
Medication
Self-medication in HVA patients with systemic reac-
tions in the past, is crucial and remains an important 
part of the patient’s education in view of the guidelines. 
Recently, an EAACI position paper on this topic has been 
published [32]. Real-life practice is highly compliant with 
the guidelines and currently most Polish centres pre-
scribed adrenaline auto-injectors (AAI) either regardless 
of severity of the systemic reaction to all patients with 
mastocytosis and these referred for diagnosis, or for 
those with a history of reactions of at least 2 to 4 grades 
in Mueller’s scale. What is important to note is that still 
half of the centres prescribe AAI to all patients follow-
ing the termination of treatment, as they did pre VIT. 
This may show either doctors’ medico-legal fear or their 
doubts in the successful immunoprotection following VIT, 
in spite of its documented high therapeutical effective-
ness achieved after 5 years of treatment (approximately 
90–100% in wasp venom allergy and approximately 80% 
in bee venom allergy) [33–35]. Questions regarding the 
AAI prescription following VIT treatment were neither 
included in the questionnaire previously used in Poland, 
nor by the British or French authors [13–16]. 
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Both, previous and current EAACI guidelines recom-
mend antihistamine premedication to reduce the num-
ber and severity of large local reactions as well as mild 
dermal (urticaria, angioedema) systemic reactions [6, 12]. 
Currently in Poland, antihistamine premedication is used 
less commonly in comparison to our previous study, re-
gardless of the reason: in all patients (55% vs. 73%), in 
those with local reaction to VIT (39% vs. 46%), as well 
as in case of systemic reactions during VIT (7% vs. 27%) 
[14]. Stable values of antihistamine premedication are re-
ported in the UK. Routine application of the medication 
is conducted by 40% of respondents in all VIT-treated 
patients [13, 15], similarly to France, where premedica-
tion has been used systematically or occasionally by less 
than half of practitioners (42% vs. 30%, respectively) [16]. 
The previous EAACI guidelines strongly encouraged to 
discontinue β-blockers and ACE-inhibitors in VIT-treated 
patients [6]. The current body of evidence indicates that 
anaphylaxis does not occur more frequently in patients 
receiving β-blockers, but the older population with car-
diovascular comorbidities are at an increased risk of 
more severe systemic reactions, and weak response to 
adrenaline intervention. It seems also that the risk of 
ACEI continuation might be overestimated, leaving the 
problem within the narrow group of certain patients with 
cardiovascular comorbidities [36]. The safety of cardio-
vascular treatment along with VIT is also indicated in the 
Polish real-life study [37]. Our data show that less than 
half of the Polish centres discontinued β-blockers and 
less than a quarter did so for ACEI (Table 4). In the UK, 
much more centres, than in Poland, decide to drop both 
β-blockers (62%) and ACEI (78%) [15].
Differencesinhealthsystemorganizationcan
influenceprocedures
Due to the differences in the health system organiza-
tion between the European countries, there is a method-
ological difference in the way the surveys were conduct-
ed. In Poland, VIT is performed only by allergy specialists 
in allergy centres. Hence, the respondents of our study 
were allergologists, one per centre. For this reason, we 
obtained responses from almost all centres dealing with 
HVA; therefore, the presented results are very close to 
real numbers. Whereas in both French and British stud-
ies, respondents were individual doctors involved in VIT 
practice [13, 15, 16]. In the UK, VIT is conducted by either 
allergists or immunologists, while in France by allergy, 
pneumonology or dermatology specialists as well as by 
paediatricians [13, 15, 16]. Additionally, VIT in Poland is 
exclusively performed at the secondary and tertiary level. 
The electronic way of questionnaire completion could 
have also improved the response rate. We may assume 
that financing and health care structures differ across 
these three countries. This may have a major impact 
on the setting (out-patient vs. in-patient) of treatment 
as well as the kind of the protocol administered. Health 
system organization seems to influence the doctor’s 
involvement, protocol preference and locations of pro-
cedure, what we have already indicated in our previous 
studies [14]. 
As a limitation of our questionnaire, we should in-
dicate two areas which were omitted: safety matters, 
investigated by British authors [13] and the selection of 
patients to VIT, investigated by the French authors [16]. 
DifferencesintheEAACIguidelines2005vs.2017
with respect to Polish real-life practice
The newest evidence-based EAACI VIT guidelines are 
for the first time produced using the Appraisal of Guide-
lines for Research & Evaluation (AGREE II) approach, to 
guarantee the most objective current knowledge [38]. 
Table 4 presents a summary of the real-life Polish prac-
tices in a comparison to the 2005 and 2017 guidelines 
and shows the updated recommendations; some which 
were only slightly changed and others which were fully 
reformulated after 12 years [6, 12].
Conclusions
The audit is an indispensable tool to verify compli-
ance with recommendations in everyday practice. In the 
most important procedures, in Poland we have obtained 
a very high compliance with the guidelines, which shows 
that Polish specialists are well educated regarding VIT. 
Nevertheless, we have also observed a large spread of 
results in these areas where the guidelines are not pre-
cisely defined. Inclusion of all stages of treatment and 
more regular updates of guidelines would facilitate the 
unification of the medical procedures. 
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